Lilly's Trulicity OK'd; can it top GLP-1 market?

Watch out Novo Nordisk, GlaxoSmithKline and AstraZeneca.

Watch out Novo Nordisk, GlaxoSmithKline and AstraZeneca.

Lilly is about to flex its muscles once again in the US diabetes market – winning the FDA's blessing on...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category